ADMA Biologics (NASDAQ:ADMA) Director Jerrold Grossman Buys 12,500 Shares

ADMA Biologics Inc (NASDAQ:ADMA) Director Jerrold Grossman bought 12,500 shares of the firm’s stock in a transaction on Monday, May 11th. The shares were acquired at an average cost of $8.01 per share, with a total value of $100,125.00. Following the purchase, the director directly owned 501,384 shares of the company’s stock, valued at approximately $4,016,085.84. This represents a 2.56% increase in their position. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website.

ADMA Biologics Stock Up 6.7%

Shares of ADMA stock traded up $0.53 during trading hours on Tuesday, hitting $8.41. 8,218,842 shares of the company’s stock traded hands, compared to its average volume of 5,610,034. The company has a quick ratio of 3.93, a current ratio of 6.95 and a debt-to-equity ratio of 0.51. The stock’s fifty day simple moving average is $11.83 and its two-hundred day simple moving average is $15.38. ADMA Biologics Inc has a 12-month low of $7.21 and a 12-month high of $22.37. The stock has a market cap of $2.00 billion, a price-to-earnings ratio of 12.37 and a beta of 0.83.

ADMA Biologics (NASDAQ:ADMA) last posted its quarterly earnings results on Wednesday, May 6th. The biotechnology company reported $0.19 earnings per share for the quarter, hitting the consensus estimate of $0.19. ADMA Biologics had a return on equity of 39.98% and a net margin of 32.43%.The company had revenue of $114.49 million for the quarter, compared to the consensus estimate of $139.98 million. During the same quarter in the prior year, the business posted $0.11 EPS. The firm’s quarterly revenue was down .3% compared to the same quarter last year. On average, analysts expect that ADMA Biologics Inc will post 0.84 EPS for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of ADMA. State Street Corp lifted its holdings in ADMA Biologics by 0.3% in the fourth quarter. State Street Corp now owns 13,597,259 shares of the biotechnology company’s stock valued at $248,014,000 after acquiring an additional 35,614 shares during the period. Sachem Head Capital Management LP grew its stake in shares of ADMA Biologics by 27.0% during the 4th quarter. Sachem Head Capital Management LP now owns 11,375,000 shares of the biotechnology company’s stock valued at $207,480,000 after purchasing an additional 2,415,000 shares during the period. Westfield Capital Management Co. LP increased its position in shares of ADMA Biologics by 36.9% during the 4th quarter. Westfield Capital Management Co. LP now owns 6,992,907 shares of the biotechnology company’s stock valued at $127,551,000 after purchasing an additional 1,886,105 shares during the last quarter. Capital Research Global Investors increased its position in shares of ADMA Biologics by 104.0% during the 4th quarter. Capital Research Global Investors now owns 6,637,472 shares of the biotechnology company’s stock valued at $121,067,000 after purchasing an additional 3,383,559 shares during the last quarter. Finally, Nuveen LLC lifted its stake in shares of ADMA Biologics by 3.5% in the 4th quarter. Nuveen LLC now owns 5,926,390 shares of the biotechnology company’s stock worth $108,097,000 after purchasing an additional 202,245 shares during the period. Hedge funds and other institutional investors own 75.68% of the company’s stock.

Analyst Ratings Changes

Several brokerages have recently weighed in on ADMA. Wall Street Zen downgraded ADMA Biologics from a “buy” rating to a “hold” rating in a report on Monday, May 4th. Zacks Research cut shares of ADMA Biologics from a “strong-buy” rating to a “hold” rating in a research note on Monday, April 27th. Mizuho cut their price objective on shares of ADMA Biologics from $24.00 to $20.00 and set an “outperform” rating on the stock in a research report on Thursday, May 7th. Cantor Fitzgerald restated a “neutral” rating on shares of ADMA Biologics in a research note on Thursday, March 26th. Finally, Canaccord Genuity Group decreased their target price on shares of ADMA Biologics from $21.00 to $18.00 and set a “buy” rating for the company in a report on Thursday, May 7th. Two investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, ADMA Biologics presently has a consensus rating of “Hold” and a consensus price target of $19.00.

About ADMA Biologics

ADMA Biologics, Inc is a biopharmaceutical company headquartered in Ramsey, New Jersey, that focuses on the development, manufacturing and commercialization of specialty plasma-derived biologics for the treatment of primary immunodeficiency and infectious diseases. Leveraging an integrated model that spans plasma collection, fractionation, formulation and fill-finish operations, ADMA Biologics aims to address unmet needs in immune-compromised and high-risk patient populations.

The company’s marketed product portfolio includes BIVIGAM, a human immunoglobulin intravenous (IGIV) therapy approved by the U.S.